Astec LifeSciences 将来の成長

Future 基準チェック /56

Astec LifeSciences利益と収益がそれぞれ年間100.8%と32.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に18.2% 100.9%なると予測されています。

主要情報

100.8%

収益成長率

100.9%

EPS成長率

Chemicals 収益成長	23.0%
収益成長率	32.9%
将来の株主資本利益率	18.2%
アナリストカバレッジ	Low
最終更新日	04 Nov 2024

今後の成長に関する最新情報

Recent updates

Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation Package

Jul 23

Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% Higher

Jul 03

Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Mar 15

Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital

May 17

Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value

Oct 14

We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Jul 27

Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly

Jun 28

A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)

Jun 03

Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)

May 08

Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 06

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Jan 25

Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?

Dec 13

We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay Packet

Jul 21

Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?

May 02

The Trend Of High Returns At Astec LifeSciences (NSE:ASTEC) Has Us Very Interested

Apr 17

Do Astec LifeSciences's (NSE:ASTEC) Earnings Warrant Your Attention?

Apr 02

Is Astec LifeSciences Limited's (NSE:ASTEC) Shareholder Ownership Skewed Towards Insiders?

Mar 18

Declining Stock and Solid Fundamentals: Is The Market Wrong About Astec LifeSciences Limited (NSE:ASTEC)?

Jan 28

What Does Astec LifeSciences Limited's (NSE:ASTEC) Share Price Indicate?

Jan 17

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Jan 08

I Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Dec 28

Is Astec LifeSciences Limited (NSE:ASTEC) Popular Amongst Insiders?

Dec 18

業績と収益の成長予測

NSEI:ASTEC - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	9,575	933	252	964	2
3/31/2026	7,857	636	162	773	2
3/31/2025	6,242	-711	-136	1,183	1
9/30/2024	3,729	-1,036	-422	119	N/A
6/30/2024	3,852	-785	N/A	N/A	N/A
3/31/2024	4,586	-469	-1,253	102	N/A
12/31/2023	4,317	-509	N/A	N/A	N/A
9/30/2023	4,981	-258	-1,580	101	N/A
6/30/2023	5,871	60	N/A	N/A	N/A
3/31/2023	6,285	256	-426	747	N/A
12/31/2022	7,735	736	N/A	N/A	N/A
9/30/2022	8,297	975	-448	351	N/A
6/30/2022	7,325	883	N/A	N/A	N/A
3/31/2022	6,769	899	-804	236	N/A
12/31/2021	5,803	708	N/A	N/A	N/A
9/30/2021	5,230	531	-800	483	N/A
6/30/2021	5,754	619	N/A	N/A	N/A
3/31/2021	5,587	650	-1,107	-82	N/A
12/31/2020	5,698	723	N/A	N/A	N/A
9/30/2020	5,786	774	1,190	1,885	N/A
6/30/2020	5,639	648	N/A	N/A	N/A
3/31/2020	5,287	475	1,231	1,684	N/A
12/31/2019	4,844	291	N/A	N/A	N/A
9/30/2019	4,781	269	-420	32	N/A
6/30/2019	4,507	331	N/A	N/A	N/A
3/31/2019	4,382	357	-375	153	N/A
12/31/2018	4,246	402	N/A	N/A	N/A
9/30/2018	3,781	374	N/A	N/A	N/A
6/30/2018	3,611	325	N/A	N/A	N/A
3/31/2018	3,676	349	N/A	647	N/A
12/31/2017	3,254	212	N/A	N/A	N/A
9/30/2017	3,119	148	N/A	N/A	N/A
6/30/2017	3,008	192	N/A	N/A	N/A
3/31/2017	2,987	191	N/A	192	N/A
12/31/2016	3,167	-29	N/A	N/A	N/A
9/30/2016	2,865	-114	N/A	N/A	N/A
6/30/2016	2,643	-206	N/A	N/A	N/A
3/31/2016	2,330	50	N/A	-125	N/A
12/31/2015	2,629	-115	N/A	N/A	N/A
9/30/2015	2,777	61	N/A	N/A	N/A
6/30/2015	2,728	84	N/A	N/A	N/A
3/31/2015	2,669	148	N/A	75	N/A
12/31/2014	2,212	131	N/A	N/A	N/A
9/30/2014	2,147	127	N/A	N/A	N/A
6/30/2014	2,156	96	N/A	N/A	N/A
3/31/2014	2,070	87	N/A	146	N/A
12/31/2013	2,179	97	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ASTECは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 6.7% ) よりも高い成長率であると考えられます。

収益対市場: ASTEC今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ASTEC今後 3 年以内に収益を上げることが予想されます。

収益対市場: ASTECの収益 ( 32.9% ) Indian市場 ( 10.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: ASTECの収益 ( 32.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ASTECの自己資本利益率は、3年後には低くなると予測されています ( 18.2 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/20 01:51
終値	2024/12/20 00:00
収益	2024/09/30
年間収益	2024/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Astec LifeSciences Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。8

アナリスト	機関
null null	Asian Markets Securities Private Limited
Ankur Periwal	Axis Capital Limited
Satish Kumar	CGS International

Astec LifeSciences 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target decreased by 14% to ₹1,090

Price target decreased by 14% to ₹1,108

Price target decreased by 9.3% to ₹1,205

Price target decreased to ₹1,923

Price target increased to ₹2,132

Price target increased to ₹1,869

Recent updates

Astec Lifesciences Limited Announces Appointment of Arijit Mukherjee as the Manager

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Astec Lifesciences Limited Announces Resignation of Brahma Nand Vyas as an Independent Director

Price target decreased by 14% to ₹1,090

Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024

New major risk - Revenue and earnings growth

Insufficient new directors

Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation Package

Astec LifeSciences Limited to Report Q1, 2025 Results on Jul 29, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% Higher

Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astec Lifesciences Limited Announces Resignation of Mr. K. Suryanarayan as Chief Financial Officer, Effective May 3, 2024

Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024

Price target decreased by 14% to ₹1,108

Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Price target decreased by 9.3% to ₹1,205

Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)

Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024

Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)

Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023

Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023

Upcoming dividend of ₹1.50 per share at 0.1% yield

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock

Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)

Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023

Price target decreased to ₹1,923

High number of new directors

Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)

Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer

Astec LifeSciences Limited to Report Q2, 2023 Results on Oct 28, 2022

Investor sentiment improved over the past week

Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value

Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer

Price target increased to ₹2,132

High number of new directors

We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director

Astec LifeSciences Limited to Report Q1, 2023 Results on Jul 25, 2022

Upcoming dividend of ₹1.50 per share

Full year 2022 earnings: Revenues exceed analyst expectations

Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)

Price target increased to ₹1,869

Consensus revenue estimates increase by 11%

Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)

Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

MD & Director recently bought ₹37m worth of stock

Astec LifeSciences Limited Announces Cessation of Ashok Hiremath as the Managing Director of the Company

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹1.5m worth of stock

Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹2.4m worth of stock

Price target increased to ₹1,508